Scholarlink

Main purpose <p>Endoscopic management offers acceptable oncologic control in select patients with upper tract urothelial carcinoma (UTUC) while preserving renal function. Adjuvant intracavitary treatment with chemotherapy or Bacillus Calmette-Guérin (BCG) has been proposed to reduce recurrence risk. We aimed to evaluate the impact of adjuvant intracavitary treatment on ipsilateral UTUC recurrence following endoscopic management.</p> Materials and methods <p>We queried a multi-institutional cohort of patients who underwent endoscopic management for UTUC. Treatment groups were defined as no instillation, single post-operative instillation, or multiple instillations. Ipsilateral UTUC recurrence-free survival (RFS) was estimated using Kaplan-Meier curves and Cox proportional hazards models evaluated factors associated with recurrence.</p> Results <p>A total of 599 renal units, of which 43 received single instillation and 86 multiple instillations, in 334 patients treated endoscopically for UTUC were analyzed. The median follow-up time for patients without recurrence was 12 months (IQR 4–33). Multiple adjuvant instillations of any intracavitary treatment were associated with a significantly improved RFS (HR 0.52, 95% CI 0.34–0.79), whereas a single instillation was not associated with a significant reduction in recurrence (HR 0.64, 95% CI 0.37–1.13). This association between multiple instillations and improved RFS remained significant after adjustment for clinical risk factors, including tumor grade (adjusted HR 0.36, 95% CI 0.16–0.81), and was confirmed in sensitivity analyses limited to patients with primary UTUC (HR 0.46, 95% CI 0.26–0.85).</p> Conclusion <p>Multiple intracavitary instillations of BCG or chemotherapy after endoscopic management of UTUC were associated with longer ipsilateral RFS. These findings suggest a potential benefit of repeated instillations and warrant prospective validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Patterns of adjuvant intracavitary instillation and recurrence after endoscopic management of upper tract urothelial carcinoma

  • 期刊论文

  • 发表日期：

    2026年5月19日

查看全文
  • Philipp Korn,
  • Maximilian Pallauf,
  • Jaime O. Herrera-Caceres,
  • Soum Lokeshwar,
  • Mark Essien,
  • Alexander Small,
  • Dima Raskolnikov,
  • Nir Kleinmann,
  • Asaf Shvero,
  • Surena F. Matin,
  • Craig Labbate,
  • Hristos Kaimakliotis,
  • Isamu Tachibana,
  • Jennifer Linehan,
  • Jane Choe,
  • Ojas Shah,
  • Miyad Movassaghi,
  • William Huang,
  • Jesse Persily,
  • Aaron Perecman,
  • David Canes,
  • Rodrigo R. Pessoa,
  • Aaron Potretzke,
  • Jay D. Raman,
  • Nirmish Singla

摘要

Main purpose

Endoscopic management offers acceptable oncologic control in select patients with upper tract urothelial carcinoma (UTUC) while preserving renal function. Adjuvant intracavitary treatment with chemotherapy or Bacillus Calmette-Guérin (BCG) has been proposed to reduce recurrence risk. We aimed to evaluate the impact of adjuvant intracavitary treatment on ipsilateral UTUC recurrence following endoscopic management.

Materials and methods

We queried a multi-institutional cohort of patients who underwent endoscopic management for UTUC. Treatment groups were defined as no instillation, single post-operative instillation, or multiple instillations. Ipsilateral UTUC recurrence-free survival (RFS) was estimated using Kaplan-Meier curves and Cox proportional hazards models evaluated factors associated with recurrence.

Results

A total of 599 renal units, of which 43 received single instillation and 86 multiple instillations, in 334 patients treated endoscopically for UTUC were analyzed. The median follow-up time for patients without recurrence was 12 months (IQR 4–33). Multiple adjuvant instillations of any intracavitary treatment were associated with a significantly improved RFS (HR 0.52, 95% CI 0.34–0.79), whereas a single instillation was not associated with a significant reduction in recurrence (HR 0.64, 95% CI 0.37–1.13). This association between multiple instillations and improved RFS remained significant after adjustment for clinical risk factors, including tumor grade (adjusted HR 0.36, 95% CI 0.16–0.81), and was confirmed in sensitivity analyses limited to patients with primary UTUC (HR 0.46, 95% CI 0.26–0.85).

Conclusion

Multiple intracavitary instillations of BCG or chemotherapy after endoscopic management of UTUC were associated with longer ipsilateral RFS. These findings suggest a potential benefit of repeated instillations and warrant prospective validation.